NasdaqGM - Delayed Quote USD
Theravance Biopharma, Inc. (TBPH)
At close: October 18 at 4:00 PM EDT
After hours: October 18 at 4:02 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 3 | 3 | 4 |
| Avg. Estimate | -0.23 | -0.2 | -1.01 | 0.06 |
| Low Estimate | -0.28 | -0.25 | -1.14 | -0.68 |
| High Estimate | -0.19 | -0.17 | -0.9 | 0.61 |
| Year Ago EPS | -0.17 | -0.17 | -1 | -1.01 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 4 | 4 | 4 |
| Avg. Estimate | 15.34M | 16.2M | 60.2M | 87.47M |
| Low Estimate | 14M | 14M | 57.1M | 58.81M |
| High Estimate | 16.8M | 18.6M | 64.1M | 123M |
| Year Ago Sales | 15.69M | 17.57M | 57.42M | 60.2M |
| Sales Growth (year/est) | -2.20% | -7.80% | 4.80% | 45.30% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.21 | -0.15 | -0.25 | -0.21 |
| EPS Actual | -0.17 | -0.17 | -0.24 | -0.34 |
| Difference | 0.04 | -0.02 | 0.01 | -0.13 |
| Surprise % | 19.00% | -13.30% | 4.00% | -61.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.23 | -0.2 | -1.01 | 0.06 |
| 7 Days Ago | -0.23 | -0.2 | -1.01 | 0.06 |
| 30 Days Ago | -0.23 | -0.2 | -1.01 | 0.06 |
| 60 Days Ago | -0.23 | -0.2 | -1.01 | 0.06 |
| 90 Days Ago | -0.19 | 0.01 | -0.65 | 0.13 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | TBPH | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -35.30% | -- | -- | 3.70% |
| Next Qtr. | -17.60% | -- | -- | 7.90% |
| Current Year | -1.00% | -- | -- | 2.50% |
| Next Year | 105.90% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 54.10% | -- | -- | 11.88% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/16/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 8/6/2024 |
| Maintains | TD Cowen: Hold to Hold | 8/6/2024 |
| Downgrade | Leerink Partners: Outperform to Market Perform | 8/6/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/29/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/14/2024 |
Related Tickers
GLTO Galecto, Inc.
7.12
+5.79%
SPRO Spero Therapeutics, Inc.
1.2800
-0.39%
BOLT Bolt Biotherapeutics, Inc.
0.6264
-1.82%
HLVX HilleVax, Inc.
1.8800
+0.53%
ASMB Assembly Biosciences, Inc.
18.24
+0.77%
SEER Seer, Inc.
1.9300
-0.52%
ANTX AN2 Therapeutics, Inc.
1.0500
+1.94%
ACHL Achilles Therapeutics plc
1.0000
+1.01%
PMVP PMV Pharmaceuticals, Inc.
1.5800
-1.25%
OKUR OnKure Therapeutics, Inc.
18.51
+3.12%